Home » Newsletters » BioWorld Asia

BioWorld Asia

Sep. 13, 2000

View Archived Issues

PowderJect To Pay US$79.2M For Celltech's Vaccine Arm

Cureon To Develop Therapeutic Applications Of LNA Platform

Cell Therapy More Promising After Stem Cell Breakthrough

Peptor Diabetes Drug Looks Promising At Phase II Interim

European Parliament Condemns British Decision To Allow Cloning

Antisoma Harnesses Cyanide, Antibodies For Cancer Therapy

Medarex To Create Antibodies For OGS Proteomics Targets

IsoTis Gearing Up For Trials, October Stock Market Float

ExonHit Raises US$12M, Prepares For IPO In 2001

Biotie Targets Inflammation Protein With Dual Activity

Amrad Advances Clinical Slate, Including HBV, Pain Therapies

Other News To Note

Bionomics Seeking Partners For Cancer, Epilepsy Genes

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 29, 2026.
ENCALS 2026: From genetics to advancing strategies against ALS
BioWorld Science
Amyotrophic lateral sclerosis (ALS)-associated genes provide direct therapeutic targets and reveal pathways that can be used to develop treatments that counteract...
Next wave of BCI firms builds on pioneers to tackle challenges
BioWorld
With the pace of neurotechnology development accelerating, a wave of brain-computer interface (BCI) companies is emerging on the heels of the pioneers. In the...
Boehringer Ingelheim identifies new mGlu3 receptor agonists
BioWorld Science
Boehringer Ingelheim Pharma GmbH & Co. KG and Vanderbilt University have discovered new dihydrobenzoxazine compounds acting as metabotropic glutamate mGlu3...
GT-02897 exerts efficacy in preclinical multiple myeloma
BioWorld Science
Investigators from the Karl Landsteiner University aimed to evaluate the therapeutic potential of a novel CDK9 inhibitor/degrader, GT-02897, for the potential...